Introduction: Atopic dermatitis (AD) is a chronic and relapsing inflammatory skin disease characterized by severe pruritus and eczematous skin lesions. Subcutaneous immunotherapy (SCIT) refers to repeated contact with gradually increasing doses of allergen extracts, which improve patient tolerance to such allergens and controls, or reduces allergic symptoms. This study aimed to explore the long-term efficacy and safety of SCIT for patients with AD sensitized to house-dust mite (HDM). Methods: We conducted a retrospective analysis of 378 patients with HDM-sensitized AD. Among these patients, 164 received SCIT plus pharmacotherapy for 3 years (SCIT group) and the other 214 patients received only pharmacotherapy (non-SCIT group). The scoring atopic dermatitis (SCORAD) and pruritus visual analog scale (VAS) scores, laboratory test results, and adverse effects were recorded. Results: The SCORAD and pruritus VAS scores significantly decreased in the SCIT group. Also, the SCIT group showed higher reduction ratios of SCORAD and pruritus VAS scores than those observed in the non-SCIT group at 3 years after treatment initiation. The risk of development of new sensitization was higher in the non-SCIT group than in the SCIT group (relative risk 1.92 [95% confidence interval {CI}, 1.30-2.85]; p < 0.05). The eosinophil count of the participants significantly differed in the complete response (CR) group (p < 0.05) but not in the non-CR group (p = 0.098). However, the serum total immunoglobulin E value was not significantly reduced (p = 0.204). Of 8421 injections given to the patients, 231 injections (2.74%) showed adverse effects during the treatment period. Conclusion: Three years of SCIT can significantly reduce the severity and pruritus of moderate-to-severe AD with HDM sensitization. Patients who are multisensitized can also benefit from HDM SCIT. Patients can achieve long-term effects, such as prevention of neoallergen sensitization and inhibition of the allergy march.
Introduction: Atopic dermatitis (AD) is a chronic and relapsing inflammatory skin disease characterized by severe pruritus and eczematous skin lesions. Subcutaneous immunotherapy (SCIT) refers to repeated contact with gradually increasing doses of allergen extracts, which improve patient tolerance to such allergens and controls, or reduces allergic symptoms. This study aimed to explore the long-term efficacy and safety of SCIT for patients with AD sensitized to house-dust mite (HDM). Methods: We conducted a retrospective analysis of 378 patients with HDM-sensitized AD. Among these patients, 164 received SCIT plus pharmacotherapy for 3 years (SCIT group) and the other 214 patients received only pharmacotherapy (non-SCIT group). The scoring atopic dermatitis (SCORAD) and pruritus visual analog scale (VAS) scores, laboratory test results, and adverse effects were recorded. Results: The SCORAD and pruritus VAS scores significantly decreased in the SCIT group. Also, the SCIT group showed higher reduction ratios of SCORAD and pruritus VAS scores than those observed in the non-SCIT group at 3 years after treatment initiation. The risk of development of new sensitization was higher in the non-SCIT group than in the SCIT group (relative risk 1.92 [95% confidence interval {CI}, 1.30-2.85]; p < 0.05). The eosinophil count of the participants significantly differed in the complete response (CR) group (p < 0.05) but not in the non-CR group (p = 0.098). However, the serum total immunoglobulin E value was not significantly reduced (p = 0.204). Of 8421 injections given to the patients, 231 injections (2.74%) showed adverse effects during the treatment period. Conclusion: Three years of SCIT can significantly reduce the severity and pruritus of moderate-to-severe AD with HDM sensitization. Patients who are multisensitized can also benefit from HDM SCIT. Patients can achieve long-term effects, such as prevention of neoallergen sensitization and inhibition of the allergy march.
Authors: Abel Suárez-Fueyo; Tania Ramos; Agustín Galán; Lucia Jimeno; Peter A Wurtzen; Alicia Marin; Consolación de Frutos; Carlos Blanco; Ana C Carrera; Domingo Barber; Rosa Varona Journal: J Allergy Clin Immunol Date: 2013-11-28 Impact factor: 10.793
Authors: A Muraro; G Roberts; S Halken; I Agache; E Angier; M Fernandez-Rivas; R Gerth van Wijk; M Jutel; S Lau; G Pajno; O Pfaar; D Ryan; G J Sturm; R van Ree; E-M Varga; C Bachert; M Calderon; G W Canonica; S R Durham; H J Malling; U Wahn; A Sheikh Journal: Allergy Date: 2018-04 Impact factor: 13.146
Authors: Louis-Philippe Boulet; Helen K Reddel; Eric Bateman; Søren Pedersen; J Mark FitzGerald; Paul M O'Byrne Journal: Eur Respir J Date: 2019-08-29 Impact factor: 16.671
Authors: Maria Kristiansen; Sangeeta Dhami; Gopal Netuveli; Susanne Halken; Antonella Muraro; Graham Roberts; Desiree Larenas-Linnemann; Moises A Calderón; Martin Penagos; George Du Toit; Ignacio J Ansotegui; Jörg Kleine-Tebbe; Susanne Lau; Paolo Maria Matricardi; Giovanni Pajno; Nikolaos G Papadopoulos; Oliver Pfaar; Dermot Ryan; Alexandra F Santos; Frans Timmermanns; Ulrich Wahn; Aziz Sheikh Journal: Pediatr Allergy Immunol Date: 2016-12-12 Impact factor: 6.377